GLR1062

GLR1062 is an adeno-associated virus (AAV)-based gene therapy designed for the treatment of neovascular age-related macular degeneration (nAMD). Developed by Gan & Lee Pharmaceuticals, the therapy utilizes a viral vector to deliver a genetic payload that enables the continuous intraocular expression of an anti-vascular endothelial growth factor (anti-VEGF) protein. By providing a sustained source of anti-VEGF activity within the eye, GLR1062 aims to serve as a one-time therapeutic intervention, potentially reducing the treatment burden associated with frequent intravitreal injections of standard anti-VEGF agents. Preliminary clinical data from the GLR1062-AMD-5-01 study (ChiCTR2400086995) have demonstrated favorable safety and durable efficacy, including improvements in best-corrected visual acuity (BCVA) and reductions in central retinal thickness (CRT).